Navigation Links
NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
Date:8/4/2011

LOS ANGELES, Aug. 4, 2011 /PRNewswire/ -- NeuroSigma, Inc., a Los Angeles-based medical device company, today provided an update in response to substantial interest and inquiries generated by a National Public Radio (NPR) news story which aired July 27, 2011 on the use of non-invasive Trigeminal Nerve Stimulation (TNS) for the treatment of drug-resistant epilepsy.

(http://www.npr.org/2011/07/27/138619259/new-device-reduces-seizures-no-surgery-required).

Dr. Christopher DeGiorgio, a neurologist at the University of California, Los Angeles (UCLA) and scientific advisor to NeuroSigma, who was interviewed in the NPR story, pioneered the development of TNS for epilepsy.  NeuroSigma is the exclusive licensee of UCLA's TNS intellectual property.

NeuroSigma is now planning a Phase III pivotal trial for its external TNS (eTNS™) system.  Earlier this year, Dr. DeGiorgio delivered results of the 50-subject Phase II double-blind clinical trial to the Antiepileptic Drug Trials XI Conference in Miami, Florida.  The results compared favorably with those of pharmaceuticals and surgically-implanted devices.  (http://www.prnewswire.com/news-releases/positive-results-reported-for-phase-ii-randomized-double-blind-clinical-trial-for-the-treatment-of-drug-resistant-epilepsy-using-external-trigeminal-nerve-stimulation-etns---the-usb-port-to-the-brain-120917294.html)

The study found that subjects receiving NeuroSigma's active eTNS™ treatment experienced a significant improvement in seizure reduction, while those randomized to receive the control condition ("sham" or "placebo") did not.  Subjects receiving active treatment showed a 40% responder rate after 18 weeks of daily stimulation compared to a 15% responder rate in the placebo group.  A responder is defined as someone who experiences a greater than 50% reduction in seizures.  In addition to reducing seizures, eTNS™ also improved mood.  These results confirm and extend the findings of DeGiorgio's positive feasibility trial in epilepsy, reported in 2009 in the journal, Neurology.

At the same conference, DeGiorgio also revealed a potential mechanism of action for the eTNS™ treatment of epilepsy.  Using Positron Emission Tomography (PET), significant decreases in regional cerebral blood flow were detected in several regions of the cerebral cortex, which is where seizures originate.

NeuroSigma is currently developing its next generation eTNS™ system and in 2012 anticipates filing a CE Mark application for approval to commence marketing its new eTNS™ system for the treatment of epilepsy in Europe.

In addition, in 2012, the company anticipates filing an IDE for an upcoming multi-center Phase III pivotal trial in the United States.  Neither NeuroSigma nor UCLA are currently enrolling subjects for eTNS™ epilepsy trials.

Future updates regarding clinical trials, including potential enrollment details, and study results will be posted on NeuroSigma's website (www.neurosigma.com).

CAUTION: The eTNS™ system is an investigational device and at this time is limited by United States law for investigational use only in approved research protocols.  NeuroSigma does not recommend the off-label use of nerve or muscle electrical stimulation units for any purpose not approved by the FDA because of the potential risk of injury or death.  

About NeuroSigma, Inc.

NeuroSigma is a Los Angeles-based medical technology company established to in-license and develop early stage technologies with the potential to transform medical practice.  Currently NeuroSigma has a specific focus on neuromodulation and through a majority-owned subsidiary, NSVascular, on Thin-Film Nitinol covered stents for endovascular applications.  NeuroSigma employs two therapy platforms: Trigeminal Nerve Stimulation (TNS) and Deep Brain Stimulation (DBS).  NeuroSigma has amassed significant intellectual property licensed on an exclusive basis from the University of California, Los Angeles (UCLA), including potential therapies for epilepsy, depression and post-traumatic stress disorder (PTSD) via TNS and for PTSD, obesity and cachexia via DBS.  For more information about NeuroSigma, visit their website at http://www.neurosigma.com.


'/>"/>
SOURCE NeuroSigma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma, Inc. Retains CCG Investor Relations
2. NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLAs Thin-Film Nitinol (TFN) Stent Technology for Endovascular Applications
3. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
4. Roche responds to announcement of IDEAL hepatitis C trial results
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. EPSScentral Responds to Pandemic Alert
9. Endologix Responds to Alleged Patent Infringement
10. U.S. Kidney Dialysis Community Responds to Haitis Emergency Plea for Life-Saving Dialysis Care
11. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
Breaking Medicine News(10 mins):